Slide 1: Q3 2024 Financial Results & Business Update
1 Q3 2024 Financial Results & Business Update Nasdaq: OABI November 12, 2024
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected operating expense, cash ba
Slide 3: Introduction
Omni Introduction : Matt Foehr
Slide 4: Positioning the Business for Growth and Success
4 Positioning the Business for Growth and Success Q3 MOMENTUM IN ALL KEY METRICS Strong execution within a scalable business model that is well positioned to navigate a variety of sector cycles Partner and program base continues to grow and diversify, clinical stage programs advancing Preclinical an
Slide 5: 3 New Platform License Agreements Signed in Q3
5 3 New Platform License Agreements Signed in Q3 86 ACTIVE PARTNERS AS OF 9/30/2024 Number of Active Partners 80 60 40 20 0 See our SEC filings for Active Partners definition
Slide 6: Active Programs
6 Active Programs GROWTH CONTINUES WITH 352 ACTIVE PROGRAMS Number of YTD Change in Active Programs Active Programs 300 200 100 0 See our SEC filings for Active Programs definition
Slide 7: Active Clinical Programs and Approved Products
7 Active Clinical Programs and Approved Products Number of Active Clinical Programs • 33 active clinical programs and approved products as of 9/30/2024(2) and Approved Products(1) 30 • Genmab’s GEN1057 (bispecific anti-FAPα x DR4) and Merck KGaA’s M5542 (CTLA-4 ECD fused to anti-OX40L) each entered
Slide 8: Post-Discovery Stage Programs Continue to Grow
8 Post-Discovery Stage Programs Continue to Grow >40% GROWTH IN POST-DISCOVERY STAGE PROGRAMS OVER THE LAST 24 MONTHS As of 9/30/2022 As of 9/30/2023 As of 9/30/2024 Registration: 1 Approved: 3 Registration: 1 Phase 3: 3 Registration: 0 Approved: 3 Approved: 3 Phase 2: 2 Phase 3: 1 Phase 3: 2 Precli
Slide 9: Select Partner Updates
9 Select Partner Updates RECENT DEVELOPMENTS AND UPCOMING KEY EVENTS IMVT-1402 Acasunlimab BC3195 TEV-53408 FcRn PD-L1 x 4-1BB CDH3 Anti-IL-15 Immunovant announced that a New Drug Genmab announced that based on BioCity presented interim clinical results on Teva recently disclosed Phase 1 data for Ap
Slide 10: Upcoming Scientific Presentations
10 Upcoming Scientific Presentations CONTINUED INNOVATION AND INCREASING THE VISIBILITY OF OUR TECHNOLOGY PLATFORM December 16th San Diego Building Multispecifics from in vivo Design and Implementation of , Derived Antibody Domains and A Platform for Bioinformatics Tools Facilitating Alternative Sca
Slide 11: Financial Updates
11 Financial Updates Kurt Gustafson
Slide 12: Q3 2024 vs. Q3 2023 Financial Results
12 Q3 2024 vs. Q3 2023 Financial Results ($ in millions, except per share data) Q3 2024 Q3 2023 Variance License and milestone revenue $ 1.4 $ 2.0 ($ 0.6) Service revenue 2.5 3.0 (0.5) Royalty revenue 0.3 0.5 (0.1) Total revenue 4.2 5.5 (1.3) Research & development 13.3 13.9 (0.6) General & administ
Slide 13: Balance Sheet
13 Balance Sheet ($ in millions) September 30, December 31, 2024 2023 ASSETS Current assets: Cash & investments $ 59.4 $ 87.0 Accounts receivable, net 3.5 3.8 We expect to end 2024 with a cash Other current assets 3.7 4.1 balance in the range of $50 million to Goodwill & intangible assets 228.1 239.
Slide 14: Q&A
Omni Q&A
Slide 15: Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline
Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 9/30/2024 15 PartnerM Program Source Animal Therapy Area Target Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD-1 Sugemalimab OmniRat Oncology PD-L1 Teclistamab OmniRat Oncology BCMA x CD3 Bato
Slide 16: Omni >
Omni >